Strides receives USFDA approval for Naproxen Sodium Softgel Capsules

21 Aug 2022 , 01:33 AM

Strides Pharma Science today announced that its step-down wholly owned subsidiary Strides Pharma Global Singapore has received approval for Naproxen Sodium Softgel Capsules 220 mg OTC from the United States Food Drug Administration USFDA The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug RLD Naproxen Sodium Capsules 220 mg of Bionpharma Inc Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels tablets capsules and other formats The approval for Naproxen Sodium OTC Softgel Capsules further strengthens Strides OTC portfolio for the US markets The US OTC market for Naproxen Sodium Softgel Capsules 220 mg OTC is approximately ~US$100 Mn The product will be manufactured at the companys facility at Bengaluru